• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure

    6/16/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email

    NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure

    Settlement to eliminate potential dilution from convertible notes and warrants

    Company views that this will position the Company's market capitalization to be undervalued relative to net assets

    BANGKOK, June 16, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company") today announced that it has entered into a Repurchase and Forbearance Agreement (the "Settlement Agreement") with a significant investor (the "Investor"). Under the terms of the Settlement Agreement, NewGen will repurchase all outstanding convertible notes and warrants previously issued to the Investor (the "Original Securities") pursuant to the securities purchase agreements entered into between the parties in August 2024 and April 2025 (the "Existing Securities Purchase Agreements"), and the Investor will forbear from converting the outstanding convertible notes, exercising the outstanding warrants, and effectuating additional closings under the Existing Securities Purchase Agreements, subject to the terms of the Settlement Agreement.

    The Original Securities consist of senior convertible notes and certain warrants issued under the Existing Securities Purchase Agreements, the outstanding amounts and terms of which are set forth in the Settlement Agreement and the Company's prior filings with the SEC.

    Effective as of today, the Investor shall forbear conversion of existing notes, exercise of warrants, and effectuating additional closings under the Existing Securities Purchase Agreements, for so long as the Company is not in default of its obligations thereunder. The convertible notes will be repurchased and cancelled upon full payment of the note purchase price, and the warrants will be repurchased and cancelled upon full payment of the warrant purchase price, removing potential equity dilution.

    The Company expects to emerge from the Settlement Agreement with a more simplified capital structure that provides greater clarity for existing and prospective shareholders.

    The aggregate consideration under the Settlement Agreement is payable pursuant to a scheduled instalment payment plan extending through late 2027. The Company may prepay all or any portion of the outstanding amounts at any time without penalty. Details of the Settlement Agreement may be viewed in the Company's Form-6-K filed with the SEC today.  

    Management and the board believe that the extinguishment of the potential dilution represents a meaningful reset for the Company's capital structure and equity value profile. Following the removal of these instruments, management believes the Company's equity value will more accurately reflect its underlying net asset position and long-term value potential. The Company views that it is better positioned for improved investor visibility and continued execution of initiatives intended to enhance shareholder value.

    Alfred Siu, Founder, Chairman and Chief Executive Officer of NewGen, commented, "This settlement represents a pivotal moment for NewGen. By eliminating potential dilution from the convertible note and warrants, we believe we are strengthening our capital structure. With a clear capital structure, we believe the market will have greater clarity to recognize the intrinsic value of our diversified portfolio of assets. We remain committed to executing on our strategic initiatives and delivering long-term value for our shareholders."

    The Company will continue to evaluate strategic alternatives to further enhance shareholder value, including potential future financings that do not carry similar dilutive overhang structures. With a clean capital structure in place, the Company is better positioned to pursue value-accretive strategic investments, including the potential expansion of its existing stake in K25.ai. In parallel, management recently adopted a Digital Asset Treasury strategy as part of its broader plan to diversify reserve assets and enhance long-term shareholder value.

    About NewGenIVF Group Limited

    NewGenIVF Group is a tech-forward, diversified, multi-jurisdictional growth company pursuing opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through "NewGenProperty," focused on real estate development projects in the UAE's Ras Al Khaimah Emirate; "NewGenDigital," focused on digital asset and DeFi solutions; and "NewGenSup," focused on health and longevity products and solutions. NewGenIVF's legacy business involves IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. The information contained on, or accessible through, NewGenIVF's website is not incorporated by reference into this press release and should not be considered part of this press release.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, Section 27A of the Securities Act of 1933, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident," "committed," "positioned," "outlook," "would," "may," "potential," "aim," "seek," "project," and similar expressions, or their negatives, although not all forward-looking statements contain these identifying words.

    Forward-looking statements in this press release include, but are not limited to, statements that: the Company will repurchase all outstanding convertible notes and warrants previously issued to the Investor; the anticipated effect of the Settlement Agreement and the Investor's forbearance in reducing near-term conversion and exercise risk and simplifying the Company's capital structure; the expectation that the Company is better positioned for improved investor visibility, and that the market would recognise its net asset value; the Company's ability to satisfy its scheduled instalment payment obligations through late 2027 and to exercise the optional prepayment feature; the Company's stated intention to pursue the potential expansion of its existing stake in K25.ai; management's planned implementation of its Digital Asset Treasury strategy; and the Company's stated intention to continue evaluating opportunities to further strengthen its balance sheet and capital structure.

    These forward-looking statements are based on the Company's current expectations, estimates, projections and assumptions as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, among others: the risk that the Company fails to meet one or more of its scheduled installment payment obligations, which could result in termination of the Investor's forbearances and reinstatement of the Investor's conversion, exercise and additional closing rights; market risks which may impact investor visibility and market recognition of the Company's value; the Company's ability to maintain sufficient liquidity to fund ongoing operations and satisfy its payment obligations under the Settlement Agreement through late 2027; risks associated with the Company's Digital Asset Treasury strategy, including the price volatility of digital assets; evolving and uncertain regulatory treatment of digital assets and staking activities; management's limited prior experience in the digital asset sector; risks related to the Company's ongoing business transformation and the strain such transformation places on management and operational resources; the risk that the Company's potential expansion of its stake in K25.ai or the valuation of that investment is not realized or declines; and other risks and uncertainties described in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission.

    All information provided in this press release is as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

    Contacts

    ICR, LLC

    Robin Yang

    Phone: +1 (212) 537-3847

    Email: NewgenivfIR@icrinc.com



    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $32,000 worth of shares (34,756 units at $0.92), increasing direct ownership by 72% to 83,079 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/4/26 4:08:25 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Large owner Hrt Financial Lp bought $161,919 worth of shares (165,534 units at $0.98) (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    5/27/26 1:19:20 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization

    BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company") today announced that NewGen’s total outstanding shares now stand at 10,073,535 following share issuances in connection with its strategic share purchase agreements to acquire a 10% equity interest in K25.ai. The Company’s market capitalization reached US$7,631,710 on June 18, 2026, providing a solid foundation for future growth. Management views this market capitalization as representing a substantial discount to the Company’s net asset value of approximately US$25.98 million as of December 31, 2025. The balance sheet has been further strengthened by the Company’s subsequent US$10 m

    6/22/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested

    K25.ai to complete its US$10 million Pre-A at a US$100 million valuation and is now raising its Series A to accelerate product launch and regional expansion NewGen's expanded stake and exclusive Asia-Pacific agency rights deepen its strategic participation in K25.ai's next phase of growth BANGKOK, June 18, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today announced that it has executed an agreement for a further US$4 million strategic investment in K25.ai. The transaction completes K25.ai's US$10 million Pre-A round at a US$100 million valuation and, upon completion and satisfaction of the ap

    6/18/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure

    NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes and warrants Company views that this will position the Company's market capitalization to be undervalued relative to net assets BANGKOK, June 16, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company") today announced that it has entered into a Repurchase and Forbearance Agreement (the "Settlement Agreement") with a significant investor (the "Investor"). Under the terms of the Settlement Agreement, NewGen will repurchase all outstandi

    6/16/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Chung Ho Fai

    3/A - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/16/26 6:04:07 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Large owner Hrt Financial Lp sold $50,722 worth of shares (64,945 units at $0.78), decreasing direct ownership by 78% to 18,134 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/8/26 3:11:25 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Director Siu Wing Fung Alfred exercised 56,851 units of Class B Ordinary Shares at a strike of $0.00, increasing direct ownership by 189,503% to 56,881 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/5/26 11:14:50 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/22/26 9:41:59 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/18/26 8:30:09 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/16/26 8:30:01 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGen Doubles Down on K25.ai with Additional US$4 Million Stake and Adopts Digital Asset Treasury Strategy

    NewGen's 6% Stake in K25.ai Now Valued at US$6 MillionCompany will Leverage Expertise of K25.ai's Andy Cheung to Develop Digital Asset Treasury Strategy BANGKOK, June 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today announced it has exercised its top-up option to acquire an additional 4% equity interest in AI-native livestreaming prediction market platform K25.ai, raising its total holding to 6%. The additional US$4 million investment, which supplements an initial US$2 million investment announced in May 2026, is split evenly between cash and newly issued NewGen Class A ordinary shares.

    6/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Financials

    Live finance-specific insights

    View All

    NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress

    NewGen records strong balance sheet with total assets of US$32.7 million Net profit attributable to shareholders of the Company of US$9.9 million BANGKOK, May 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today outlined several highlights of its fiscal year 2025 results and the steady progress of its continued strategic transformation. More information on NewGen's results can be found in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, (the "2025 Annual Report") which was filed with the U.S. Securities and Exchange Commission (the "SEC") in April 2026. The ful

    5/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care